Is DRMA or DRUG more undervalued in 2026?

CirclFi compares Dermata Therapeutics, Inc. (DRMA) and Bright Minds Biosciences Inc. (DRUG) using 13 institutional-grade valuation models. DRMA has a Quality of Company score of 2.8/10 while DRUG scores 4.4/10.

Which is a better buy — DRMA or DRUG?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do DRMA and DRUG valuations compare?

DRMA at $1.35 and DRUG at $89.49 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

DRMA vs DRUG Valuation Comparison 2026 — Intrinsic Value Analysis

DRMA

Biotechnology

Dermata Therapeutics, Inc.

Quality

2.8

out of 10

Value Trap

LOW

Price

$1.35

Last close

Models

7/13

Active

DRUG

Biotechnology

Bright Minds Biosciences Inc.

Quality

4.4

out of 10

Value Trap

SAFE

Price

$89.49

Last close

Models

8/13

Active

Model-by-Model Comparison

Model	Type	DRMA Fair Value	DRMA Upside	DRUG Fair Value	DRUG Upside
Bayesian DCF	Intrinsic	$1.31	-3.2%	$24.06	-73.1%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$1.26	-6.3%	$1.42	-98.3%
PWERM	Option-Based	$1.53	+13.7%	$85.26	-4.7%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for DRMA vs DRUG — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

DRMA vs DRUG — Which Stock Is More Undervalued?

DRUG scores higher with a 4.4/10 quality rating vs DRMA's 2.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Dermata Therapeutics, Inc. (DRMA) and Bright Minds Biosciences Inc. (DRUG) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

DRMA currently trades at $1.35 with a QOC of 2.8/10, while DRUG trades at $89.49 with a QOC of 4.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).